Alphatec (NASDAQ:ATEC) & Calmare Therapeutics (NASDAQ:CTTC) Head-To-Head Analysis

Alphatec (NASDAQ:ATEC) and Calmare Therapeutics (OTCMKTS:CTTC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for Alphatec and Calmare Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alphatec 0 0 1 0 3.00
Calmare Therapeutics 0 0 0 0 N/A

Alphatec presently has a consensus target price of $4.00, indicating a potential downside of 14.89%. Given Alphatec’s higher possible upside, research analysts plainly believe Alphatec is more favorable than Calmare Therapeutics.

Profitability

This table compares Alphatec and Calmare Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alphatec -45.29% -202.30% -27.14%
Calmare Therapeutics N/A N/A N/A

Valuation & Earnings

This table compares Alphatec and Calmare Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alphatec $91.69 million 2.44 -$28.98 million ($0.58) -8.10
Calmare Therapeutics $1.11 million 3.31 -$3.82 million N/A N/A

Calmare Therapeutics has lower revenue, but higher earnings than Alphatec.

Risk and Volatility

Alphatec has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Calmare Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.

Institutional & Insider Ownership

14.8% of Alphatec shares are held by institutional investors. Comparatively, 0.5% of Calmare Therapeutics shares are held by institutional investors. 34.3% of Alphatec shares are held by company insiders. Comparatively, 17.5% of Calmare Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Alphatec beats Calmare Therapeutics on 6 of the 11 factors compared between the two stocks.

Alphatec Company Profile

Alphatec Holdings, Inc., a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures. The company offers MIS products consisting of Battalion Lateral Spacer System and Squadron Lateral Retractor, Illico Minimally Invasive Surgery System, and BridgePoint Spinous Process Fixation System; and fixation products, such as Arsenal Screw System and Zodiac Spinal Fixation Systems. It also provides cervical and cervico-thoracic products, including Trestle Luxe Anterior Cervical Plate System, and Solanas Posterior Cervico/Thoracic Fixation System and Avalon Occipital Plate; and interbody Systems, such as Battalion Universal Spacer System, Novel PEEK and Titanium Spinal Spacers, and Alphatec Solus Locking ALIF Spinal Spacer. In addition, the company offers biologics consisting of AlphaGraft Structural Allograft Spacers, AlphaGraft ProFuse Demineralized Bone Scaffold, Amnioshield Amniotic Tissue Barrier, Alphagraft Demineralized Bone Matrix, and Neocore Osteoconductive Matrix. It sells its products through a network of independent distributors and direct sales representatives in the United States. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Calmare Therapeutics Company Profile

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.